2022
Interferon-γ resistance and immune evasion in glioma develop via Notch-regulated co-evolution of malignant and immune cells
Parmigiani E, Ivanek R, Rolando C, Hafen K, Turchinovich G, Lehmann FM, Gerber A, Brkic S, Frank S, Meyer SC, Wakimoto H, Günel M, Louvi A, Mariani L, Finke D, Holländer G, Hutter G, Tussiwand R, Taylor V, Giachino C. Interferon-γ resistance and immune evasion in glioma develop via Notch-regulated co-evolution of malignant and immune cells. Developmental Cell 2022, 57: 1847-1865.e9. PMID: 35803280, DOI: 10.1016/j.devcel.2022.06.006.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBrain NeoplasmsCell Transformation, NeoplasticCytokinesGliomaHumansImmune EvasionInterferon-gammaMiceReceptors, NotchTumor MicroenvironmentConceptsTumor-associated microglia/macrophagesGlioma cellsImmune surveillanceMicroglia/macrophagesImmune cell populationsBrain tumor cellsMouse glioma cellsCytokine expressionImmune attackImmune cellsMouse modelImmune evasionSuppression of NotchTumor cellsNotch inhibitionTumor initiationUpregulation of oncogenesNotch activityCell populationsGliomasCellsSurveillanceLow Notch activityNiche controlTherapy
2021
Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas
Yeung J, Yaghoobi V, Miyagishima D, Vesely MD, Zhang T, Badri T, Nassar A, Han X, Sanmamed MF, Youngblood M, Peyre M, Kalamarides M, Rimm DL, Gunel M, Chen L. Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas. Neuro-Oncology 2021, 23: 1922-1935. PMID: 33914067, PMCID: PMC8563319, DOI: 10.1093/neuonc/noab075.Peer-Reviewed Original ResearchConceptsColony-stimulating factor-1Myeloid cellsMalignant meningiomasTumor microenvironmentCSF1/CSF1RRNA-seqRNA sequencingHuman meningiomasImmune subsetsGene expressionT cellsTreatment strategiesNormalization cancer immunotherapyImportant regulatorCell typesNovel immunocompetent murine modelDeath ligand 1 (PD-L1) expressionCell death receptor-1Immunosuppressive myeloid cellsDeath receptor-1Ligand 1 expressionFactor 1Immune cell typesImmunocompetent murine modelEffective treatment strategies